Maira M. Pires, Ph.D.
Affiliations: | 2013 | Biochemistry and Molecular Biophysics | Columbia University, New York, NY |
Area:
Molecular Biology, OncologyGoogle:
"Maira Pires"Mean distance: (not calculated yet)
Parents
Sign in to add mentorRamon E. Parsons | grad student | 2013 | Columbia | |
(Basal-like breast cancer: Modeling its initiation and characterizing novel EGFR variants.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Lau YK, Du X, Rayannavar V, et al. (2014) Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget. 5: 10503-17 |
Pires MM, Aaronson SA. (2014) Brachyury: a new player in promoting breast cancer aggressiveness. Journal of the National Cancer Institute. 106 |
Marshall N, Sanchez F, Llobet D, et al. (2014) Abstract 432: BIN3 is a novel 8p21 tumor suppressor gene that regulates the attachment checkpoint in epithelial cells Cancer Research. 74: 432-432 |
Keniry M, Pires MM, Mense S, et al. (2013) Survival factor NFIL3 restricts FOXO-induced gene expression in cancer. Genes & Development. 27: 916-27 |
Pires MM, Hopkins BD, Saal LH, et al. (2013) Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. Cancer Biology & Therapy. 14: 246-53 |
Lau Y, Pires M, Shaw J, et al. (2010) Abstract PD03-05: A Novel Combination Therapy for Triple Negative Breast Cancer: Erlotinib and Metformin Cancer Research. 70 |
Saal LH, Gruvberger-Saal SK, Persson C, et al. (2008) Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genetics. 40: 102-7 |